Zoledronic acid in the treatment of Paget’s disease and other benign bone disorders

References

• Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64(11), 1197–1211 (2004).
   PubMed Web of Science ®Google Scholar
• Green JR. Bisphosphonates: preclinical review. Oncologist 9(Suppl. 4), 3–13 (2004).
   PubMed Web of Science ®Google Scholar
• Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J. Clin. Invest. 97(12), 2692–2696 (1996).
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP et al. Structure–activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296(2), 235–242 (2001).
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) (In Press).
   Google Scholar
• Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9(5), 745–751 (1994).
   PubMed Web of Science ®Google Scholar
• Binkley N, Kimmel D, Bruner J et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J. Bone Miner. Res. 13(11), 1775–1782 (1998).
   PubMed Web of Science ®Google Scholar
• Glatt M. The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. Eur. Cell Mater. 1, 18–26 (2001).
   PubMedGoogle Scholar
• Gasser JA, Green JR. Zoledronic acid administered as a single intravenous dose preserves cancellous bone in ovariectomized rats without causing ‘frozen bone’. Bone 32(5 Suppl. 1), S221 (2003).
   Google Scholar
• Sims NA, Green JR, Glatt M et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis. Rheum. 50(7), 2338–2346 (2004).
   PubMed Web of Science ®Google Scholar
• Herrak P, Gortz B, Hayer S et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis. Rheum. 50(7), 2327–2337 (2004).
   PubMed Web of Science ®Google Scholar
• Aclasta Summary of Product Characteristics. Novartis Pharma. Basel, Switzerland (2004).
   Google Scholar
• Siris ES, Roodman GD. Paget’s disease of Bone. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Fifth Edition. Favus MJ (Ed.), American Society for Bone and Mineral Research, DC, USA, 495–506 (2003).
   Google Scholar
• Hosking DJ, Meunier PJ, Ringe JD, Reginster JY, Gennari C. Paget’s disease of bone: diagnosis and management. Br. Med. J. 312, 491–494 (1996).
   PubMedGoogle Scholar
• Hosking D. Paget’s disease. In: Hosking D, Ringe JD (Eds), Treatment of Metabolic Bone Disease. Management Strategy and Drug Therapy. London, UK (2000).
   Google Scholar
• Briesacher B, Orwig D, Seton M, Omar M, Kahler KH. Costs of treating Paget’s disease in a privately insured population. 27th Annual Meeting of the American Society for Bone and Mineral Research. TN, USA, September 23–27 2005.
   Google Scholar
• Selby PL, Davie MWJ, Ralson SH, Stone MD. Guidelines on the management of Paget’s disease of Bone. Bone 31(3), 10–19 (2002).
   Google Scholar
• Delmas PD, Meunier PJ. The management of Paget’s disease of Bone. N. Engl. J. Med. 336(8), 558–566 (1997).
   PubMed Web of Science ®Google Scholar
• Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of Bone. J. Bone Miner. Res. 16(8), 1379–1387 (2001).
   PubMed Web of Science ®Google Scholar
• Gutteridge DH, Ward LC, Stewart GO et al. Paget’s disease: acquired resistance to one aminobisphosphonate with retained response to another. J. Bone Miner. Res. 14(Suppl.2), 79–84 (1999).
   PubMedGoogle Scholar
• Chung G, Keen RW. Zoledronate treatment in active Paget’s disease. Ann. Rheum. Dis. 62(3), 275–276 (2003).
   PubMedGoogle Scholar
• Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronic acid in Paget’s disease of Bone. Calcif. Tissue Int. 60(5), 415–418 (1997).
   PubMed Web of Science ®Google Scholar
• Buckler H, Fraser W, Hosking D et al. Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study. Bone 24(5 Suppl.), S81–S85 (1999).
   PubMed Web of Science ®Google Scholar
• Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases Type II collagen breakdown in patients with Paget’s disease of Bone. Bone 28(5), 461–464 (2001).
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med. 353, 898–908 (2005).
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Better osteoporosis management a priority. Impact predicted to soar with aging population. JAMA 293(20), 2453–2458 (2005).
   PubMed Web of Science ®Google Scholar
• Cosman F. The prevention and treatment of osteoporosis: a review. Medscape Gen. Med. 7(2), 1–22 (2005).
   Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3), 271–287 (2004).
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346(9), 653–661 (2002).
   PubMed Web of Science ®Google Scholar
• Jarrett S, Conaghan P, Sloan V et al. Evidence for symptomatic benefit of the nitrogen-containing bisphosphonate zoledronic acid (ZOL) in rheumatoid arthritis (RA). EULAR 2005. Vienna, Austria, 8–11 June (2005).
   Google Scholar
• Jarrett S, Conaghan P, Papanastasiou P et al. Profound effect of zoledronic acid on bone mineral density in rheumatoid arthritis. EULAR 2004. Berlin, Germany, 9–12 June (2004).
   Google Scholar
• Jarrett S, O’Connor P, Conaghan P et al. First evidence of structural benefit from a bisphosphonate, zoledronic acid, in rheumatoid arthritis. Ann. Rheum. Dis. 63(Suppl. 1), 58 (2004).
   Google Scholar
• Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R. Treatment of Gorham’s disease with zoledronic acid. Oral Oncol. 41(7), 747–750 (2005).
   PubMed Web of Science ®Google Scholar
• Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 63(3), 1130–1136 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. 65(1), 304–309 (2004).
   PubMedGoogle Scholar
• Poole K, Warburton E, Loveridge N, Rose C, Reeve J. Preserving hip bone mineral density following stroke using intravenous zoledronic acid: findings from a 1 year randomized controlled trial. Bone 34(Suppl. 1), S95–S96 (2004).
   Google Scholar
• Shapiro JR, Beck TJ, Mustapha B, Ruff CB, Ballard P, Caminis J. Zoledronic acid counteracts bone loss in the spinal cord injury model of microgravity. J. Bone Miner. Res. 19(Suppl. 1), S445 (2004).
   Google Scholar
• Black DM, Rosario-Jansen T, Cauley JA et al. HORIZON-Pivotal Fracture Trial (PFT): unique design of a randomized, placebo-controlled trial to examine the effect of annual infusion of zoledronic acid on hip and spine fracture reduction. 31st European Symposium on Calcified Tissues. Nice, France, 5–9 June (2004).
   Google Scholar
• Colon-Emeric CS, Caminis J, Suh TT et al. The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr. Med. Res. Opin. 20(6), 903–910 (2004).
   PubMed Web of Science ®Google Scholar
• Hartl FC, Betchyk, Zhank J et al. Prevention of subsequent osteoporotic fractures after a hip fracture: the HORIZON-RFT study design and baseline data of subjects. 31st European Symposium on Calcified Tissues. Nice, France, 5–9 June (2004).
   Google Scholar
• Mikulec KH, Delaney MF, Hurwitz S, LeBoff MS. Safety and efficacy of zoledronic acid: a chart review. J. Bone Miner. Res. 18(Suppl. 1), M321 (2003).
   Google Scholar
• Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353(1), 99–102 (2005).
   PubMed Web of Science ®Google Scholar
• ADRAC Report. Bisphosphonates and osteonecrosis of the jaw. Med. J. Aust. 182(8), 417–418 (2005).
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth B, Altundag K et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. 27th Annual Meeting of the American Society for Bone and Mineral Research. TN, USA, 23–27 September (2005), (Abstract 1218).
   Google Scholar
• Siris ES. Paget’s disease of bone: treatment philosophy for the twenty-first century. Bone 24(5), 55S–56S (1999).
   Google Scholar